medRxiv : the preprint server for health sciences · 2025
Polygenic Scores of Core-1 Alzheimer's Disease Biomarkers Predict Early Cognitive and Pathological Change.
СтатьяПрепринтНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xu Yuexuan, Qiao Min, Gunasekaran Tamil I, Gu Yian, Reyes-Dumeyer Dolly, Piriz Angel, Sanchez Danurys, Soriano Belisa, Franco Yahaira, Coronado Zoraida Dominguez, Recio Patricia, Mejia Diones Rivera, Medrano Martin, Lantigua Rafael A, Honig Lawrence, Wilson Rachael, Manly Jennifer J, Brickman Adam M, Engelman Corinne D, Johnson Sterling, Asthana Sanjay, Vardarajan Badri, Mayeux Richard
Аннотация
BACKGROUND: Core-1 biomarkers, such as amyloid PET, capture the earliest biological changes leading to Alzheimer's disease (AD). While APOE is a major genetic factor, the contribution of other variants to Core-1 biomarkers remains unclear. The goal of this study is to determine whether genetic regulators of Core-1 biomarker levels predict AD pathology better than genetic regulators of clinical AD.
METHODS: Among 955 non-Hispanic white individuals, PGSs were built using GWAS of amyloid PET, plasma P-tau181, CSF P-tau181, and clinical AD. Hispanic-specific PGSs were constructed in 515 individuals using plasma P-tau181 and clinical AD GWAS. Baseline and longitudinal associations with plasma biomarkers and cognition were assessed, and replication was conducted in separate cohorts.
RESULTS: The Core-1 biomarker PGSs predicted AD pathology and associated cognitive performance better than the AD PGS in both populations.
DISCUSSION: The Core-1 PGS show improved predictive value for AD-related plasma biomarkers and early cognitive changes.
METHODS: Among 955 non-Hispanic white individuals, PGSs were built using GWAS of amyloid PET, plasma P-tau181, CSF P-tau181, and clinical AD. Hispanic-specific PGSs were constructed in 515 individuals using plasma P-tau181 and clinical AD GWAS. Baseline and longitudinal associations with plasma biomarkers and cognition were assessed, and replication was conducted in separate cohorts.
RESULTS: The Core-1 biomarker PGSs predicted AD pathology and associated cognitive performance better than the AD PGS in both populations.
DISCUSSION: The Core-1 PGS show improved predictive value for AD-related plasma biomarkers and early cognitive changes.